Literature DB >> 6344718

Primary and reactivated toxoplasma infection in patients with cardiac transplants. Clinical spectrum and problems in diagnosis in a defined population.

B J Luft, Y Naot, F G Araujo, E B Stinson, J S Remington.   

Abstract

We have attempted to define the serologic criteria for diagnosis of toxoplasmosis in heart transplant recipients. Of 31 patients who were seronegative before transplantation, 4 received a heart from a seropositive donor, and 3 of these 4 had seroconversion and developed life-threatening toxoplasmosis; the remaining 27 did not have seroconversion or develop clinical toxoplasmosis. Of 19 patients who had antibodies to Toxoplasma before transplantation, 10 developed significant increases in test titers of the dye test or double-sandwich IgM enzyme-linked immunosorbent assay but did not develop a clinical illness that could be attributed to toxoplasma infection. Significant serologic changes occurred more often in patients who received azathioprine, corticosteroids, and antithymocyte globulin than in those who received cyclosporine, corticosteroids, and antithymocyte globulin (p less than 0.05). These data show the wide clinical spectrum and differences in kinetics of antibody response of patients who develop toxoplasma infection after transplantation, and suggest that clinical disease occurs in those who have seroconversion but is rare in patients with preexisting antibody who have serologic evidence of recrudescence.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6344718     DOI: 10.7326/0003-4819-99-1-27

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  32 in total

1.  Lack of utility of specific immunoglobulin G antibody avidity for serodiagnosis of reactivated toxoplasmosis in immunocompromised patients.

Authors:  B Mechain; Y J Garin; F Robert-Gangneux; J Dupouy-Camet; F Derouin
Journal:  Clin Diagn Lab Immunol       Date:  2000-07

2.  Cardiac Transplantation: Pre-transplant Infectious Diseases Evaluation and Post-transplant Prophylaxis.

Authors:  Susan Keay
Journal:  Curr Infect Dis Rep       Date:  2002-08       Impact factor: 3.725

Review 3.  Central nervous system infection during immunosuppression.

Authors:  Joseph R Zunt
Journal:  Neurol Clin       Date:  2002-02       Impact factor: 3.806

4.  A transmembrane domain-containing surface protein from Toxoplasma gondii augments replication in activated immune cells and establishment of a chronic infection.

Authors:  Angela M Pollard; Sini Skariah; Dana G Mordue; Laura J Knoll
Journal:  Infect Immun       Date:  2009-07-06       Impact factor: 3.441

Review 5.  Infection in the bone marrow transplant recipient and role of the microbiology laboratory in clinical transplantation.

Authors:  M T LaRocco; S J Burgert
Journal:  Clin Microbiol Rev       Date:  1997-04       Impact factor: 26.132

6.  The host-parasite relationship of Toxoplasma gondii in the brains of chronically infected mice.

Authors:  D J Ferguson; W M Hutchison
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1987

7.  In vitro cultivation of Toxoplasma gondii cysts in astrocytes in the presence of gamma interferon.

Authors:  T C Jones; K A Bienz; P Erb
Journal:  Infect Immun       Date:  1986-01       Impact factor: 3.441

8.  Self-limited Toxoplasma parasitemia after liver transplantation.

Authors:  S Kusne; J S Dummer; M Ho; T Whiteside; B S Rabin; L Makowka; C O Esquivel; T E Starzl
Journal:  Transplantation       Date:  1987-09       Impact factor: 4.939

9.  Central nervous system toxoplasmosis with an increased proportion of circulating gamma delta T cells in a patient with hyper-IgM syndrome.

Authors:  L E Leiva; J Junprasert; D Hollenbaugh; R U Sorensen
Journal:  J Clin Immunol       Date:  1998-07       Impact factor: 8.317

10.  Detection of circulating antigens in immunocompromised patients during reactivation of chronic toxoplasmosis.

Authors:  E Candolfi; F Derouin; T Kien
Journal:  Eur J Clin Microbiol       Date:  1987-02       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.